Contact UPA at 800-868-1292 or info@porphyria.org
Sign Up to receive news and information, treatment and therapy updates, and to learn about current and upcoming research initiatives.
We look forward to serving you!
UPA is proud to share the updated comic book adventure featuring young Shadow Jumpers who tackle a UV villain with the knowledge and power they have gained from their experiences with EPP. This book was developed as an evidence-based resource resulting from a recent publication.
Dr. Bruce Wang (Porphyria Expert, USCF and UPA Scientific Advisory Board Member) will be taking your questions live on Saturday, February 18 at 1 PM ET on our Porphyria Together Facebook group.
We welcome you to join Porphyria Together, a new closed Facebook group where you will find helpful information in a safe community setting. JOIN US online!
PORPHYRIA PUBLICATION ALERT
UPA Scientific Advisory Board Member Amy Dickey, MD (Mass General Hospital) in the Journal of the American Academy of Dermatology. Prospective observational pilot study of quantitative light dosimetry in erythropoietic protoporphyria, this study explored novel strategies for measuring light tolerance in patients with EPP.
NEW RESEARCH OPPORTUNITIES
EPP
DISC MEDICINE - BITOPERTIN?
Phase 2 Clinical Trial for patients with EPP.
CLICK HERE to receive more information.
EPP/XLP
CIMETIDINE
A research study is underway to assess treatment with Cimetidine in patients ages 15+ with EPP/XLP. (Note: there is no longer a requirement to experience symptoms within 30-minutes of sunlight exposure.)
ALL PORPHYRIAS
(EPP, XLP, CEP, VP, AIP, HCP, PCT, HEP, ADP)
LONGITUDINAL STUDY: Long-Term Follow-Up Study to Better Understanding the Natural History of Porphyria.
AHP
Medication Study to Inform Drug Safety
Online observational study to create an updated list of medications that are risky or safe for people with one of the acute porphyrias.
AIP
AIP INTERVIEWS: 60-Minute interview with porphyria specialists to discuss patient experience.
AIP
AIP Gene Modifier Study
Study to find other genes that may make a person with AIP more or less likely to develop acute attacks.
EPP/XLP
EPP/XLP Gene Modifier Study
Study investigating genetic factors associated with differences in light sensitivity among patients with EPP and XLP.
To learn more about study details and how to participate, contact UPA at 1-800-868-1292 or info@porphyria.org.
UPA ON YOUTUBE – SCIENTIFIC ADVISORY BOARD VIDEO SERIES
The UPA Scientific Advisory Board contributed to a video series highlighting responses to questions regarding porphyria diagnosis, management, and treatment. Access videos HERE.
JOIN US FOR WHAT'S UP, DOC? LIVE
Dr. Bruce Wang (Porphyria Expert, UCSF and UPA Scientific Advisory Board Member)
Saturday, FEB 18 @ 1pm ET to answer your questions live on our Porphyria Together Facebook group. Join the group HERE
NIH RARE DISEASE DAY FEB 28
National Institutes of Health event to initiate and discuss important topics in rare disease research, the people they impact, and the collaborations that are advancing critical research.
This year's event will feature a session with UPA Member Jennifer Beck & UPA President Kristen Wheeden!
VIEW AGENDA & REGISTER HERE
(held both online and in-person)
We welcome you to join Porphyria Together, a new closed Facebook group where you will find helpful information in a safe community setting. JOIN US online!
The United Porphyrias Association is committed to improving the quality of life of the porphyria patient community and is relentlessly focused on advancing disease awareness, research, and therapies in all the porphyrias.
A world where patients are free from the pain and challenges of porphyria.
"I was diagnosed at the age of 6 with EPP after my parents noticed that every time I was outside I was experiencing anguishing discomfort. I never fully comprehended my diagnosis until I was able to connect with others. With the help of the UPA, I want to be able to help others live more comfortably with EPP and support the vision of a world where patients are free from the pain and challenges of porphyria. "
